Table of Contents
Metal-Based Drugs
Volume 2008 (2008), Article ID 576104, 6 pages
http://dx.doi.org/10.1155/2008/576104
Review Article

Nuclear Factor-kappa B as a Resistance Factor to Platinum-Based Antineoplasic Drugs

1Laboratorio de Biología Molecular, Subdirección de Investigación Básica, Instituto Nacional de Cancerológica, Avenida San Fernando 22, Tlalpan 14080, Mexico
2Genómica Funcional de Cáncer de Laboratorio, Instituto Nacional de Medicina Genomita, Mexico City 03020, Mexico

Received 12 July 2007; Accepted 18 December 2007

Academic Editor: Rafael Moreno-Sanchez

Copyright © 2008 Vilma Maldonado Lagunas and Jorge Meléndez-Zajgla. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Platinum drugs continue to be major chemotherapy drugs for cancer treatment. Nevertheless, acquired or intrinsic resistance to these compounds is common in human tumors. One important mechanism for this resistance is the avoidance of cells entering the apoptotic pathway. Nuclear factor-kappa B (NF-kappa B, NF-κB) is a pleiotropic transcription factor key in determining the death threshold of human cells. This factor is important in the final response of cells to platinum drugs, as exemplified by in vitro and in vivo models showing that inhibition of NF-κB sensitizes cancer cells to the effects of these drugs. New approaches focusing on the inhibition of NF-κB could help to minimize or even eliminate intrinsic or acquired resistance to platinum drugs.